中华医学杂志（英文版）2012，Vol.125Issue(20)：3640-3645,6.DOI:10.3760/cma.j.issn.0366-6999.2012.20.008
Folfox4 regimen administered through combined hepatic arterial and systemic infusion for treatment of colorectal cancer with unresectable liver metastases
Folfox4 regimen administered through combined hepatic arterial and systemic infusion for treatment of colorectal cancer with unresectable liver metastases
GUAN Mei 1NING Xiao-hong 1BAI Chun-mei 1CHEN Shu-chang 1YING Hong-yan 1ZHAO Lin 1LI Xiao-yuan 1ZHOU Jian-feng 1SHAO Ya-juan 1YANG Xian-da 1LIN Yi1
作者信息
- 1. Department of Medical Oncology, Peking Union Medical College Hospital, Beijing 100730, China
- 折叠
摘要
Abstract
Background Hepatic arterial infusion chemotherapy for liver metastases is under evaluation because of the high target dose and low general toxicity.To investigate the efficacy and safety of a Folfox4 regimen administered through a combined hepatic arterial and systemic infusion for the first-line treatment of colorectal cancer (CRC) with unresectable liver metastases.Methods Twenty-seven CRC patients with unresectable hepatic metastases and no prior chemotherapy were enrolled into the study They received a Folfox4 regimen; 1st day:HA(I) of oxaliplatin 85 mg/m2 and L-folinic acid 200 mg/m2,followed by a bolus hepatic arterial injection of 5-fluorouracil 400 mg/m2,then continuous HAl of 5-FU 600 mg/m2; 2nd day:infusion of L-folinic acid 200 mg/m2 i.v.followed by an intravenous bolus injection of 5-Fluorouracil 400 mg/m2,then continuous infusion of 5-fluorouracil 600 mg/m2 i.v.The patients received HA(I) during the odd cycles,and the intravenous administration of the same Folfox4 regimen during the even cycles.Results A total of 236 treatment cycles were given with a median of 10 cycles.The therapy generated the following results after six treatment cycles:complete response (CR) 1/27 (3.7％),partial response (PR) 17/27 (63.0％),stable disease (SD) 6/27 (22.2％),and progress disease (PD) 3/27 (11.1％).Five patients had hepatectomy.The serum levels of both carcinoembryonic antigen (CEA) and CA19-9 were significantly reduced (P＜0.05).A median time to progression of 11 months and a median overall survival of 24 months were documented.The major adverse events included grade 1/2 nausea/vomiting,upper abdominal pain,peripheral neuropathy,and neutropenia/thrombocytopenia.Conclusions The Folfox4 regimen administered through combined hepatic arterial and systemic infusions is efficacious and safe for the treatment of CRC with unresectable liver metastases,and it facilitates the control of local lesions.关键词
hepatic arterial infusion/colorectal cancer/liver metastasesKey words
hepatic arterial infusion/colorectal cancer/liver metastases引用本文复制引用
GUAN Mei,NING Xiao-hong,BAI Chun-mei,CHEN Shu-chang,YING Hong-yan,ZHAO Lin,LI Xiao-yuan,ZHOU Jian-feng,SHAO Ya-juan,YANG Xian-da,LIN Yi..Folfox4 regimen administered through combined hepatic arterial and systemic infusion for treatment of colorectal cancer with unresectable liver metastases[J].中华医学杂志（英文版）,2012,125(20):3640-3645,6.
